Does your PBM provide transparent contracts and reporting? It is time to move PBM business intelligence out of the dark ages. This white paper is the third in a series dedicated to exploring best practices to help employers understand the challenges and opportunities in building a sustainable specialty drug benefit.
Is your PBM applying rigorous clinical criteria to effectively identify and remove waste in your specialty drug benefit? Learn how misaligned coverage models and weak clinical criteria are working against plan sponsors. This white paper is the second of three dedicated to exploring best practices to help employers understand the challenges and opportunities in building a sustainable specialty drug benefit.
Are your PBM's financial interests fully aligned with yours? Learn more about the inherent financial conflicts found in traditional PBM business models. This white paper is the first of three dedicated to exploring best practices to help employers understand the challenges and opportunities in building a sustainable specialty drug benefit.
An insightful white paper published in JMCP and co-authored by our CEO Brenda Motheral.
Update your browser to view this website correctly. Update my browser now